Universal Influenza A Vaccine in Healthy Adults

Summary

The goal of this Phase 1, single- center, randomized, double blind, placebo-controlled dose-escalation study is to evaluate the safety, tolerability and immunogenicity of UFluA vaccine candidate at two dose levels and two schedules in healthy adult (18-45-year-old, inclusive) male and non-pregnant female subjects.

Timeline

Start

2021-12-01

Primary completion

2023-10-10

Completion

2023-10-10

Drugs

Indications